Eureka Therapeutics, Inc.
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Antibody agents specific for human CD19 and uses thereof (US 10,301,388) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 13, 2026The maintenance fee for Anti-ROR2 Antibodies (US 11,673,957) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Jan 7, 2027The maintenance fee for T Cell Receptor-Like Antibodies Specific for a Wti Peptide Presented by HLA-A2 (US 9,074,000) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 1 fee due Feb 15, 2027The maintenance fee for Antibodies Targeting B-Cell Maturation Antigen and Methods of Use (US 11,725,059) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 3 fees due May 5 to 28, 2027 · next May 5
- 1 fee due Jun 10, 2027The maintenance fee for T Cell Receptor-Like Antibody Agents Specific for Ebv Latent Membrane Protein 2A Peptide Presented by Human Hla (US 10,501,559) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Nucleic Acid Molecules Encoding Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor (US 11,866,478) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Antibodies Targeting B-Cell Maturation Antigen and Methods of Use (US 10,562,972) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Antibodies Targeting G-Protein Coupled Receptor and Methods of Use (US 10,590,196) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 2 fees due Oct 23 to 28, 2027 · next Oct 23
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,074,000 | T Cell Receptor-Like Antibodies Specific for a Wti Peptide Presented by HLA-A2 In force · High confidence | In force | High confidence | |
| US 10,562,972 | Antibodies Targeting B-Cell Maturation Antigen and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 10,590,196 | Antibodies Targeting G-Protein Coupled Receptor and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 10,633,426 | Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,906,956 | Methods of Treatments Using Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor In force · Medium confidence | In force | Medium confidence | |
| US 10,947,314 | Antibodies Targeting B-Cell Maturation Antigen and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 11,566,071 | Nucleic Acid Molecules Encoding ANTI-GPRC5D Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 11,725,059 | Antibodies Targeting B-Cell Maturation Antigen and Methods of Use In force · Low confidence | In force | Low confidence | |
| US 11,820,806 | Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,866,478 | Nucleic Acid Molecules Encoding Chimeric Antigen Receptors Targeting G-Protein Coupled Receptor In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 39: 8 patents in force now held by others · 8 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 8 abandoned · 14 no status recorded